ArriVent BioPharma, Inc.
AVBPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with. With a market capitalization of $1.55B, it sits in small-cap territory. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Market Cap
$1.55B
Beta
1.30
P/E (TTM)
—
P/E (Fwd)
-9.48
EPS (TTM)
$-3.43
EPS (Fwd)
$-3.50
ROE
-55.2%
ROA
-34.7%
Cash
$326.4M
Total Debt
$419,000
Free CF
-$82.8M
52W Change
50.5%
Annual Financials
Cash vs Debt
ArriVent BioPharma, Inc. holds $326.4M in cash against $419K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$82.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -55.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, AVBP has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AVBP.